A real‐world study of dacomitinib in later‐line settings for advanced non‐small cell lung cancer patients harboring EGFR mutations

OBJECTIVE: Dacomitinib has been approved for the first‐line treatment of non‐small cell lung cancer (NSCLC) carrying classical epidermal growth factor receptor (EGFR) mutations; however, real‐world data on its later‐line application are lacking. MATERIALS AND METHODS: Patients’ data were retrospecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Hong‐Shuai, Zhang, Jin‐Yao, Yan, Xiang, Xu, Hai‐Yan, Hao, Xue‐Zhi, Xing, Pu‐Yuan, Wang, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8855913/
https://www.ncbi.nlm.nih.gov/pubmed/35023313
http://dx.doi.org/10.1002/cam4.4495

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8855913/
https://www.ncbi.nlm.nih.gov/pubmed/35023313
http://dx.doi.org/10.1002/cam4.4495

Ejemplares similares